Suppr超能文献

接受ombitasvir、paritaprevir/r + dasabuvir + 利巴韦林治疗的乙肝病毒合并丙肝病毒感染且伴有代偿性肝硬化患者的乙肝病毒再激活风险

Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirin.

作者信息

Preda C M, Popescu C P, Baicus C, Constantinescu I, Oproiu A, Voiosu T, Diculescu M, Negreanu L, Gheorghe L, Sporea I, Trifan A, Ceausu E, Proca D, Manuc M

机构信息

UMF "Carol Davila" Gastroenterology & Hepatology Department, Clinic Fundeni Institute, Bucharest, Romania.

UMF "Carol Davila" Virology Department, Victor Babes Hospital, Bucharest, Romania.

出版信息

J Viral Hepat. 2018 Jul;25(7):834-841. doi: 10.1111/jvh.12872. Epub 2018 Feb 21.

Abstract

Hepatitis B virus may reactivate in patients with chronic hepatitis C treated with direct-acting antivirals. The aim of this study was to investigate the risk of hepatitis B virus (HBV) reactivation in HBV + hepatitis C virus (HCV)-co-infected patients with compensated liver cirrhosis treated with paritaprevir/ombitasvir/ritonavir, dasabuvir with ribavirin. We reviewed prospectively gathered data from a national cohort of 2070 hepatitis C virus patients with compensated liver cirrhosis who received reimbursed paritaprevir/ombitasvir/r, dasabuvir with ribavirin for 12 weeks from the Romanian National Health Agency during 2015-2016. Twenty-five patients in this cohort were HBs antigen positive (1.2%); 15 untreated with nucleotide analogues agreed to enter the study. These patients were followed up: ALT monthly, serology for HBV and DNA viral load at baseline, EOT and SVR at 12 weeks. Hepatitis B virus (HBV)-co-infected patients were all genotype 1b and 52% females, with a median age of 60 years (51 ÷ 74); 76% were pretreated with peginterferon + ribavirin; 72% were with severe necroinflammatory activity on FibroMax assessment; 40% presented comorbidities; and all were HBe antigen negative. Hepatitis C virus (HCV) SVR response rate was 100%. Hepatitis B virus (HBV)-DNA viral load was undetectable in 7/15 (47%) before therapy, and for the other 8 patients, it varied between below 20 and 867 IU/mL. Five patients (33%) presented virological reactivation (>2 log increase in HBV-DNA levels) during therapy. One patient presented with hepatitis associated with HBV reactivation, and two started anti-HBV therapy with entecavir. Hepatitis B virus (HBV) virological reactivation was present in 33% in our patients. Generally, HBV-DNA elevations were mild (<20 000 IU/mL); however, we report one case of hepatitis associated with HBV reactivation.

摘要

接受直接抗病毒药物治疗的慢性丙型肝炎患者中,乙型肝炎病毒可能会重新激活。本研究的目的是调查接受帕利瑞韦/奥比他韦/利托那韦、达沙布韦联合利巴韦林治疗的代偿期肝硬化的乙肝病毒(HBV)和丙型肝炎病毒(HCV)合并感染患者中HBV重新激活的风险。我们前瞻性地回顾了罗马尼亚国家卫生机构在2015年至2016年期间收集的全国队列中2070例接受代偿期肝硬化治疗的丙型肝炎病毒患者的数据,这些患者接受了12周的帕利瑞韦/奥比他韦/利托那韦、达沙布韦联合利巴韦林治疗并获得报销。该队列中有25例患者HBs抗原呈阳性(1.2%);15例未接受核苷酸类似物治疗的患者同意参加研究。对这些患者进行随访:每月检测ALT,在基线、治疗结束时(EOT)和12周持续病毒学应答(SVR)时检测HBV血清学和DNA病毒载量。HBV合并感染患者均为1b基因型,52%为女性,中位年龄为60岁(51÷74);76%曾接受聚乙二醇干扰素+利巴韦林治疗;72%在FibroMax评估中具有严重坏死性炎症活动;40%有合并症;且均为HBe抗原阴性。HCV的SVR应答率为100%。7/15(47%)的患者在治疗前HBV-DNA病毒载量检测不到,其他8例患者的病毒载量在20至867IU/mL之间。5例患者(33%)在治疗期间出现病毒学重新激活(HBV-DNA水平增加>2 log)。1例患者出现与HBV重新激活相关的肝炎,2例开始使用恩替卡韦进行抗HBV治疗。我们的患者中33%出现HBV病毒学重新激活。一般来说,HBV-DNA升高程度较轻(<20000IU/mL);然而,我们报告了1例与HBV重新激活相关的肝炎病例。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验